Axiogenesis AG Company Profile

01:48 EST 19th November 2017 | BioPortfolio

The business objective of Axiogenesis lies in the area of clinical (red) biotechnology, specifically in the production of stem cell-based assays that enable drug development. These innovative and proprietary assays accelerate and improve drug candidate selection, lower costs and thus increase overall drug development efficiency. At present the main focus is heart muscle disease (cardiomyopathy).

Since early 2008, the first products of Axiogenesis have been actively marketed and are already generating significant turnovers.

This range of products has been further developed during the last months employing groundbreaking human induced Pluripotent Stem cell (iPS) technology. Through in-house development of human iPS technology, the next product generation of murine embryonic stem cells will be complemented with human stem cell-derived tissues.

With this technology it is possible to reverse-differentiate (or de-differentiate) adult human cells (e.g., skin or blood cells) to an artificial embryonic state. Using proprietary technology, Axiogenesis then forward-differentiates these into pure organ specific cells and defined tissues. Proof of concept of this two-step method was established in-house during November 2008. The first human, organ-specific iPS cells will be available for sale by the end of 2011.

A range of tissue models (including heart, liver and nerve) will be produced through the proliferation and differentiation of genetically modified stem cells. These are used to test efficacy and potential adverse side effects of drug candidates.

Increased drug development efficiency, with the use of Axiogenesis technology, is achieved through:

  • Earlier selections against drug candidates that will have high adverse side affects or do not have a therapeutic effect.
  • Early selection and fast tracking of drug candidates with high efficacy and low side effects.
  • Partial substitution of costly animal studies.
  • Reduction of the time taken for preclinical studies.
  • Extension of marketing exclusivity gained through a shorter drug development cycle, resulting in a longer time from market authorization until patent protection is lost.

Furthermore the system lends itself to product line extension through rapid testing of side effect profiles and improvements in efficacy of modified compounds or through the identification of novel indications of existing active pharmaceutical ingredients (APIs).


Nattermannallee 1/S20


Phone: +49-221-998818-0
Fax: +49-221-998818-10

News Articles [5 Associated News Articles listed on BioPortfolio]

Ncardia nach Fusion von Pluriomics und Axiogenesis gegründet

Grundlage gebildet, um der führende Anbieter für hiPSC-basierte Drug Discovery- Lösungen zu werden Axiogenesis und Pluriomics fusionieren zu Ncardia ( Das Privatunternehmen, das i....

Ncardia Established Following Pluriomics Axiogenesis Merger

  Life Sciences Jobs   ...

Ncardia Established Following Pluriomics Axiogenesis Merger

Builds foundation to become the trusted leader in hiPSC based drug discovery solutions Ncardia ( has been established following the merger of Pluriomics...

Axiogenesis AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25072017] Prices from USD $250

SummaryAxiogenesis AG Axiogenesis is a preclinical biotechnology company that specializes in development and production of stem cellderived cell types. The company offers products such as cardiac cell...

Ncardia Signs License Agreement with First Pharmaceutical Partner for Disease Modeling Patent Portfolio

Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate companies gain access to key disease modeling patents from Ncardia. This press rel...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

Axiogenesis AG

The business objective of Axiogenesis lies in the area of clinical (red) biotechnology, specifically in the production of stem cell-based assays that enable drug development. These innovative and pr...

More Information about "Axiogenesis AG" on BioPortfolio

We have published hundreds of Axiogenesis AG news stories on BioPortfolio along with dozens of Axiogenesis AG Clinical Trials and PubMed Articles about Axiogenesis AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Axiogenesis AG Companies in our database. You can also find out about relevant Axiogenesis AG Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Corporate Database Quicklinks

Searches Linking to this Company Record